BioNotebook: Ambit, Xencor, Soligenix, Ampio

 
• By Mandy Jackson

Ambit stock drops on no accelerated filing for quizartinib; Xencor prices IPO, rises in first day; Soligenix starts Phase II orBec study; and Ampio updates Phase III Ampion status.

More from Alimentary/Metabolic

More from Therapy Areas